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and placebo was also signiﬁcant (p < 0.001) with the shortest times
observed with diclofenac-N. Treatment-emergent AEs were similar across
treatment groups with similar rates in subjects treated with placebo
(52.9%), diclofenac-N 35mg (60.8%) and diclofenac-N 18mg (55.1%).
Conclusions: An investigational, proprietary, nano-formulated, lower
dose, oral diclofenac demonstrated good efﬁcacy, onset of action, and
tolerability. As suggested by this phase-2 clinical trial, use of this lower
dose formulation could maintain efﬁcacy, shorten onset of action, and
possibly result in an improved tolerability proﬁle for patients with acute
arthritic pain.
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THE APPLICATION OF PLATELET-RICH PLASMA IN EARLY
OSTEOARTHRITIS OF KNEE
S-J. Jang. Kosin Univ. Gospel Hosp., Busan, Korea, Republic of
Purpose: Platelet-rich plasma (PRP) is a natural concentrate of
autologous blood growth factors experimented in different ﬁelds of
medicine in order to test its potential to enhance tissue regeneration,
and so emerged as a treatment option for tendinopathies and chronic
wounds. In addition to release of growth factors, PRP also promotes
concentrated anti-inﬂammatory signals including interleukin-1a, which
has been a focus of emerging treatments for osteoarthritis. The
primary objective is to compare a single, intra-articular injection of
platelet-rich plasma (PRP) with hyruan injection in patients with early
osteoarthritis of knee and to assess the clinical efﬁcacy and safety of
intra-articular platelet-rich plasma (PRP) injection in patients with low
degree osteoarthritis (OA) of the knee.
Methods: Between June 2008 and October 2010, we reviewed the
results of 86 consecutive primary osteoarthritic patients underwent
intra-articular injection of PRP.In a group of early osteoarthritis patients,
inclusion criteria was set to those who were able to be followed up for
at least 6 months and showed as Kellgren-Lawrence grade I on simple
radiograph or MRI, and exclusion criteria was set as severe obesity,
infection, immunosuppressed patients, advanced osteoarthritis(K-L grade
I, II, III), and severe deformity. PRP was injected once, in principle. Also,
to compare the effects of PRP, hyruan injection was performed in 21
cases during the same period in a same target group, and the effect
was compared by perfoming 3 times in an interval of 1 week. Results
were evaluated at 4, 8, 12, 18, 24 weeks post-injection using radiologic
study, visual analogue scale (VAS) and international knee documentation
committee (IKDC) score for functional score.
Results: According to VAS, the mean preoperative scale was 8.2 (range
7–10) and the mean postoperative scale was 3.2 (range 1–4) and 2.9
(range 0–4) at 12 and 24 weeks of follow-up. In IKDC score, the
mean preoperative knee score was 57.5 points (range 32–77), and the
mean postoperative knee score was 77.3 points (range 60–95) and 88.9
points (range 69–98) at 12 and 24 weeks of follow-up, respectively.
Patients receiving PRP experienced statistically signiﬁcantly greater
improvements in VAS (p =0.032), and IKDC score measures, than patients
receiving hyruan injection. There was no different between the safety
results of the two groups. No increased risk of local adverse events was
observed in the follow-up periods.
Conclusions: According to VAS, the mean preoperative scale was 8.2
(range 7–10) and the mean postoperative scale was 3.2 (range 1–4) and
2.9 (range 0–4) at 12 and 24 weeks of follow-up. In IKDC score, the
mean preoperative knee score was 57.5 points (range 32–77), and the
mean postoperative knee score was 77.3 points (range 60–95) and 88.9
points (range 69–98) at 12 and 24 weeks of follow-up, respectively.
Patients receiving PRP experienced statistically signiﬁcantly greater
improvements in VAS (p =0.032), and IKDC score measures, than patients
receiving hyruan injection. There was no different between the safety
results of the two groups. No increased risk of local adverse events was
observed in the follow-up periods.
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A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF A
NOVEL, PROPRIETARY, NANO-FORMULATED ORAL INDOMETHACIN
G. Manvelian1, S. Daniels2. 1Independent Clinical Res. Consultant, Poway,
CA, USA; 2Premier Res. Group, Austin, TX, USA
Purpose: Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are a common
medication taken for acute pain relief. Indomethacin has a long-
established efﬁcacy and safety proﬁle yet can have a variable and
somewhat slow onset of action. Indomethacin also has the potential
for gastrointestinal adverse events (AEs), suggesting the need for a
new formulation which can safely provide fast onset of acute pain
relief. Our objective was to evaluate the analgesic efﬁcacy and safety
of an investigational, proprietary, nano-formulated, oral indomethacin
compared with placebo in subjects with acute dental pain.
Methods: This was a phase-2, multicenter, randomized, double-blind,
single-dose, parallel-group, placebo-controlled study. In total, 203
subjects were enrolled who: were 18–50 years of age, had extraction
of ≥2 third molars, and experienced moderate to severe pain intensity
within 6 hours after surgery. Subjects received either nano-formulated
indomethacin 20mg, 40mg, or placebo. The primary efﬁcacy variable
was the sum of total pain relief (TOTPAR) over 8 hours (TOTPAR-8).
Higher scores indicated better pain relief.
Results: Nano-formulated indomethacin was signiﬁcantly (p< 0.001)
better than placebo for TOTPAR-8 (mean; 95% CI): 40mg (12.56; 2.64);
20mg (10.79; 2.66); placebo (3.02; 2.64). Nano-formulated indomethacin
was also signiﬁcantly (p < 0.001) better than placebo for TOTPAR-4
(mean; 95% CI): 40mg (6.16; 4.78); 20mg (5.47; 4.61); placebo (1.63;
2.83). The difference in time to onset of analgesia between each
treatment and placebo was also signiﬁcant (p < 0.001). Treatment-
emergent AEs occurred less often in subjects treated with nano-
formulated indomethacin 20mg (38.0%) than those treated with nano-
formulated indomethacin 40mg (51.0%) or placebo (56.9%).
Conclusions: A proprietary, nano-formulated, lower dose, oral
indomethacin demonstrated good efﬁcacy, onset of action, and
tolerability. The ability to utilize a lower dose and maintain efﬁcacy
could result in an improved tolerability and safety proﬁle and is in line
with the FDA directive to use the lowest effective dose for the shortest
duration.
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CLINICAL EVALUATION OF A HERBAL FORMULATION, RHULIEF™,
IN THE MANAGEMENT OF KNEE OSTEOARTHRITIS
B. Antony1, R. Kizhakedath2, M. Benny1, B.T. Kuruvilla1. 1Arjuna Natural
Extracts Ltd., Aluva, India; 2Anugraha Med. Ctr., Kochi, India
Purpose: The study was conducted to evaluate the efﬁcacy, safety and
tolerability of Rhulief™, a unique mixture of acetyl boswellic acids
with acetyl 11-keto beta boswellic acid (AKBA) content of 10% w/w
and BCM 95®, a composition of curcumin which is about 7 times
more bioavailable than conventional curcumin, compared with non
steroidal anti-inﬂammatory drug, Celecoxib in the management of knee
Osteoarthritis.
Methods: Fifty four subjects were screened, 30 subjects were enrolled
and 28 completed the study. Subjects of both sexes aged 18 to
65 years who were medically stable with moderate form of osteoarthritis
evidenced by narrowing of the medial joint space with swelling were
randomized into two groups and were treated for a period of 12 weeks.
Gr I: Oral administration of Rhulief™ 500mg capsule twice daily
Gr II: Oral administration of Celecoxib 100mg capsule twice daily
Subjects with long standing and severe form of osteoarthritis, persons
with history of rheumatoid or reactive arthritis and signiﬁcant systemic
diseases were excluded from the study. Symptom scoring and clinical
examination were done during their each visit to ﬁnd out the efﬁcacy of
the drug. Safety of the drug was assessed by recording the liver function
test, renal function test and haemogram.
Results: The results of the symptom scoring revealed that there was a
signiﬁcant (p < 0.05) improvement in pain scores within the groups over a
period of 12 weeks and the improvement was more with Gr I. Signiﬁcant
(p < 0.05) improvement in walking distance and joint line tenderness
were also observed within the groups and the effects were greater with
Gr I. Statistically signiﬁcant difference between range of movements
were observed within both the groups (p < 0.05). The differences in
range of movements were comparable in both groups and there was
no signiﬁcant change between the two groups. Vital signs, haemogram,
liver function test and renal function test were not adversely modiﬁed by
Rhulief™. The results of the present study concluded that the treatment
was well-tolerated and did not produce any adverse effect in patients.
Conclusions: Rhulief™ at 500mg twice a day was better than Celecoxib
100mg twice daily in symptom scoring and clinical examination. It was
equally effective as Celecoxib in alleviating crepitus and range of joint
movements. The drug was well tolerated and no dose-related toxicity
was found. Efﬁcacy and tolerability of Rhulief™ used in the current
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study was shown to be superior to those of Celecoxib for treating active
osteoarthritis.
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A PILOT STUDY OF THE USE OF A TRUFIT PLUG FOR CARTILAGE REPAIR
IN THE KNEE AND HOW TO DEAL WITH EARLY CLINICAL FAILURES?
A.A. Dhollander, K. Liekens, F. Almqvist, R. Verdonk, S. Lambrecht,
D. Elewaut, G. Verbruggen, P.C. Verdonk. Ghent Univ., Ghent, Belgium
Purpose: The purpose of this pilot study is to present our short-term
experience with the TruFit plug (Smith & Nephew, Andover, MA) for
cartilage repair in the knee and to discuss our approach to treat early
clinical failures.
Methods: Twenty patients were consecutively treated for their cartilage
lesion with this plug technique. These patients were prospectively
clinically evaluated at 6 and 12 months of follow-up. Magnetic resonance
imaging (MRI) was used for morphological analysis of the cartilage repair.
Biopsy samples were taken from 3 cases during revision surgery, allowing
histological assesment of the repair tissue.
Results: The short-term clinical and MRI outcome of this pilot study
are mediocre. No signs of deterioration of the repair tissue were
observed. Three of the 15 patients (20.0%) displayed persistent or even
more clinical symptoms after insertion of the plug. These patients
were considered as failures and therefore eligible for revision surgery.
During revision surgery the repair tissue was carefully removed. The
remaining osteochondral defect was ﬁlled with autologous bone grafts.
Immediate and persistent relieve of symptoms was observed in all
3 patients. Histological assessment of biopsy specimens taken during
revision surgery of these 3 patients revealed ﬁbrous vascularized repair
tissue with the presence of foreign-body giant cells.
Conclusion: The overall short term clinical and MRI outcome of a
TruFit plug for cartilage repair in the knee is mediocre. In this pilot
study a modest clinical improvement became apparent at 12 months
of follow-up. MRI data showed no deterioration of the repair tissue.
Remarkably, 3 of the 15 patients (20%) had persistent clinical symptoms
after surgery. These patients were succesfully treated with the removal
of the osteochondral plug remnants and the application of autologous
bone grafts. Longer follow-up studies and randomised controlled trials
are mandatory to conﬁrm the ﬁndings of this pilot study.
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MID-TERM RESULTS OF THE TREATMENT OF CARTILAGE DEFECTS
IN THE KNEE USING ALGINATE BEADS CONTAINING HUMAN MATURE
ALLOGENIC CHONDROCYTES
A.A. Dhollander, P.C. Verdonk, R. Verdonk, S. Lambrecht, D. Elewaut,
G. Verbruggen, F. Almqvist. Ghent Univ., Ghent, Belgium
Purpose: The purpose of this paper was to present our mid-term
experience with the implantation of alginate beads containing human
mature allogenic chondrocytes for the treatment of cartilage lesions in
the knee.
Methods: A biodegradable, alginate-based biocompatible scaffold
containing human mature allogenic chondrocytes was used for cartilage
lesions in the knee. Twenty-one patients were clinically prospectively
evaluated with use of the Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) and a Visual Analogue Scale (VAS). The
mean follow-up time was 6.3 years (5–8 years). MRI data were analyzed
based on the MOCART (Magnetic Resonance Observation of Cartilage
Repair Tissue) system, allowing morphological assessment of the repair
tissue. MRI images were taken at one year of follow-up and at a mean
follow-up of 6.1 years (5–7 years).
Results: During the follow-up period the WOMAC and VAS scores
improved signiﬁcantly. No signs of clinical deterioration or adverse
reactions to the alginate beads/allogenic chondrocyte implantation were
observed. Four failures occured during the follow-up period in this study
(19.05%). The MOCART scoring methods indicated that the condition of
the repair tissue deteriorated on MRI.
Conclusions: This investigation provided useful information on the
efﬁcacy of this new treatment in chondral lesions of the knee. The
mid-term clinical outcome of the presented technique was promising.
However, these results were not conﬁrmed by the MRI ﬁndings.
Moreover, the MRI data indicated a deterioration of the repair tissue.
These results inspire us to search for further improvements of this
technique.
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DULOXETINE AS TREATMENT FOR KNEE PAIN IN PATIENTS
WITH OSTEOARTHRITIS WHO REGULARLY USE NONSTEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDs): A POST HOC ANALYSIS OF
TWO RANDOMIZED, PLACEBO-CONTROLLED TRIALS
M.C. Hochberg1, L. Peng2, J. Ahl2, S. Zhang3, V. Skljarevski3, P. Gaynor2,
M.M. Wohlreich2. 1Univ. of Maryland Sch. of Med., Baltimore, MD, USA;
2Lilly USA, LLC, Indianapolis, IN, USA; 3Lilly Res. Lab., Eli Lilly and Company,
Indianapolis, IN, USA
Purpose: To examine whether treatment with duloxetine has similar
efﬁcacy in patients with symptomatic knee osteoarthritis (OA) who
regularly use NSAIDs as compared with those who do not.
Methods: We conducted a post hoc analysis of data from 2 randomized,
placebo-controlled trials of duloxetine in patients with symptomatic
knee OA. In each trial, patients were randomized to 13 weeks of
treatment with duloxetine 60–120mg once daily or placebo, and
stratiﬁed according to concomitant NSAID use at baseline. NSAID users
were identiﬁed as those patients who were taking a therapeutic dose
of NSAID or acetaminophen for ≥14 days per month for 3 months
immediately preceding the study. Efﬁcacy measures were the Brief
Pain Inventory (BPI) 24-h average pain severity score (0–10), and
the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC;0–96). Missing data were imputed using last-observation-
carried-forward method. Differences in treatment effect of duloxetine
versus placebo between subgroups were analyzed with an ANCOVA
model that included therapy, study, baseline value, concomitant NSAID
use, and therapy-by-NSAID subgroup interaction. Safety and tolerability
were assessed with spontaneously reported treatment-emergent adverse
events (TEAEs).
Results: There were a total of 105 duloxetine NSAID users, 112
placebo NSAID users, 134 duloxetine non-NSAID users, and 136 placebo
non-NSAID users. Overall mean baseline ratings were BPI average
pain=6.15, and WOMAC total=51.37, and there were no signiﬁcant
differences between NSAID subgroups on these measures. Mean changes
from baseline are summarized in Figure 1. Treatment-by-NSAID use
interactions were not signiﬁcant for either of the outcome measures,
which suggests that the effect of duloxetine treatment was not affected
by concomitant NSAID use. Nausea was the most common TEAE reported
in patients treated with duloxetine vs. placebo that was signiﬁcantly
(p < 0.05) more frequent regardless of concomitant NSAID use. In addition
among NSAID users, patients treated with duloxetine vs. placebo reported
signiﬁcantly more hyperhidrosis (p < 0.05); and constipation (p < 0.01)
was reported signiﬁcantly more frequently among the non-NSAID users.
Fig. 1. Mean changes from baseline in BPI average pain severity and
WOMAC total.
Conclusions: There were a total of 105 duloxetine NSAID users, 112
placebo NSAID users, 134 duloxetine non-NSAID users, and 136 placebo
non-NSAID users. Overall mean baseline ratings were BPI average
pain=6.15, and WOMAC total=51.37, and there were no signiﬁcant
differences between NSAID subgroups on these measures. Mean changes
from baseline are summarized in Figure 1. Treatment-by-NSAID use
interactions were not signiﬁcant for either of the outcome measures,
which suggests that the effect of duloxetine treatment was not affected
by concomitant NSAID use. Nausea was the most common TEAE reported
